| Frontiers in Oncology | |
| Human antibody VH domains targeting uPAR as candidate therapeutics for cancers | |
| Oncology | |
| Wei Li1  Margaret G. Hines1  Xiaojie Chu1  John W. Mellors2  Dimiter S. Dimitrov2  Ilya Lyakhov3  | |
| [1] Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States;Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States;Abound Bio, Pittsburgh, PA, United States;Comp IL, LLC, Carnegie, PA, United States; | |
| 关键词: therapeutic antibody; VH domain; human uPAR; DbTE (domain based bispecific T cell engager); cancer; | |
| DOI : 10.3389/fonc.2023.1194972 | |
| received in 2023-03-27, accepted in 2023-07-24, 发布年份 2023 | |
| 来源: Frontiers | |
PDF
|
|
【 摘 要 】
The high expression of uPAR has been linked to tumor progression, invasion, and metastasis in several types of cancer. Such overexpression of uPAR makes it a potential target for immunotherapies across common cancers such as breast, colorectal, lung, ovarian cancer, and melanoma. In our study, two high-affinity and specific human VH domain antibody candidates, designed as clones 3 and 115, were isolated from a phage-displayed human VH antibody library. Domain-based bispecific T- cell engagers (DbTE) based on these two antibodies exhibited potent killing of uPAR-positive cancer cells. Thus, these two anti-uPAR domain antibodies are promising candidates for treating uPAR positive cancers.
【 授权许可】
Unknown
Copyright © 2023 Chu, Li, Hines, Lyakhov, Mellors and Dimitrov
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311144202357ZK.pdf | 2385KB |
PDF